These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 17893430)
1. Interaction of CpG-oligodeoxynucleotides with Toll like receptor 9 induces apoptosis and modulates metaloproteinase-2 activity in human intestinal epithelium. Khorramizadeh MR; Hosseinzadeh S; Safavifar F; Saadat F; Aalizadeh N; Falak R; Jadali Z; Pezeshki M Iran J Allergy Asthma Immunol; 2007 Sep; 6(3):107-14. PubMed ID: 17893430 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466 [TBL] [Abstract][Full Text] [Related]
3. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766 [TBL] [Abstract][Full Text] [Related]
4. Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling. Lim EJ; Lee SH; Lee JG; Chin BR; Bae YS; Kim JR; Lee CH; Baek SH FEBS Lett; 2006 Aug; 580(18):4533-8. PubMed ID: 16870179 [TBL] [Abstract][Full Text] [Related]
5. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Pedersen G; Andresen L; Matthiessen MW; Rask-Madsen J; Brynskov J Clin Exp Immunol; 2005 Aug; 141(2):298-306. PubMed ID: 15996194 [TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984 [TBL] [Abstract][Full Text] [Related]
7. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif. Zhang Z; Guo K; Schluesener HJ J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945 [TBL] [Abstract][Full Text] [Related]
8. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228 [TBL] [Abstract][Full Text] [Related]
9. Effect of toll-like receptor 3 agonists on the functionality and metastatic properties of breast cancer cell model. Alizadeh N; Amiri MM; Salek Moghadam A; Zarnani AH; Saadat F; Safavifar F; Berahmeh A; Khorramizadeh MR Iran J Allergy Asthma Immunol; 2013 May; 12(2):161-7. PubMed ID: 23754355 [TBL] [Abstract][Full Text] [Related]
10. Human lung cancer cells express functionally active Toll-like receptor 9. Droemann D; Albrecht D; Gerdes J; Ulmer AJ; Branscheid D; Vollmer E; Dalhoff K; Zabel P; Goldmann T Respir Res; 2005 Jan; 6(1):1. PubMed ID: 15631627 [TBL] [Abstract][Full Text] [Related]
11. Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression. Griebel PJ; Brownlie R; Manuja A; Nichani A; Mookherjee N; Popowych Y; Mutwiri G; Hecker R; Babiuk LA Vet Immunol Immunopathol; 2005 Oct; 108(1-2):11-6. PubMed ID: 16098606 [TBL] [Abstract][Full Text] [Related]
13. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release. Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412 [TBL] [Abstract][Full Text] [Related]
14. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111 [TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury, but provide a late window for protection against endotoxin-mediated liver damage. Slotta JE; Scheuer C; Menger MD; Vollmar B J Hepatol; 2006 Mar; 44(3):576-85. PubMed ID: 16310279 [TBL] [Abstract][Full Text] [Related]
16. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. Macfarlane DE; Manzel L J Immunol; 1998 Feb; 160(3):1122-31. PubMed ID: 9570525 [TBL] [Abstract][Full Text] [Related]
18. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. El Andaloussi A; Sonabend AM; Han Y; Lesniak MS Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541 [TBL] [Abstract][Full Text] [Related]
19. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses]. Li N; Fan XG; Tang SE; Zhu C Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582 [TBL] [Abstract][Full Text] [Related]
20. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity. Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]